Study types
- article 5
- other 1
Condition tags
- endometriosis 6
- mesh:D004715 2
- dysmenorrhea 1
- dyspareunia 1
Top journals
Frequent coauthors
OBJECTIVE: To evaluate the effects of elagolix on clinically meaningful improvements in health-related quality of life (HRQOL) measured by the EHP-30 (Endometriosis Health Profile-30). METHODS: Data from two phase III trials of elagolix fo…
Aim: To evaluate impact of co-morbidities on opioid use in endometriosis. Patients & m ethods: This was a retrospective analysis of data obtained from the Symphony Health database (July 2015–June 2018), which contains medical and pharmacy c…
PURPOSE: Elagolix is an oral gonadotropin-releasing hormone antagonist approved in the United States for the management of moderate to severe pain associated with endometriosis. We performed a real-world evaluation of the demographic and cl…
INTRODUCTION: Endometriosis is a chronic gynecologic disorder associated with several pain symptoms. This research evaluated opioids utilization following endometriosis diagnosis. METHODS: Women aged 18 to 49 who had one inpatient or 2 outp…